TG Therapeutics, Inc. (NASDAQ:TGTX) Position Decreased by Legal & General Group Plc

Legal & General Group Plc decreased its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 1.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 391,388 shares of the biopharmaceutical company's stock after selling 7,065 shares during the period. Legal & General Group Plc owned about 0.25% of TG Therapeutics worth $11,781,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of TGTX. Bleakley Financial Group LLC bought a new position in TG Therapeutics during the 4th quarter worth approximately $245,000. Castellan Group bought a new position in TG Therapeutics during the fourth quarter worth $8,539,000. Barclays PLC lifted its stake in TG Therapeutics by 83.9% during the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after purchasing an additional 158,323 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in TG Therapeutics by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock worth $16,859,000 after purchasing an additional 270,286 shares during the period. Finally, Stratos Wealth Advisors LLC bought a new stake in TG Therapeutics during the fourth quarter valued at $241,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TGTX has been the subject of several research reports. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $40.67.

TG Therapeutics Stock Performance

Shares of TGTX traded up $1.02 during mid-day trading on Tuesday, reaching $37.99. 1,285,693 shares of the company's stock traded hands, compared to its average volume of 3,101,777. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The business's 50-day moving average price is $36.61 and its 200-day moving average price is $32.13. The stock has a market capitalization of $5.97 billion, a P/E ratio of -379.86 and a beta of 2.14. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $43.32.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. The firm had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Equities analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.